Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib

Y. Y. Janjigian, H. J. Groen, L. Horn, E. F. Smit, Y. Fu, F. Wang, M. Shahidi, L. J. Denis, W. Pao, V. A. Miller

OnderzoeksoutputAcademic

Vingerafdruk

Duik in de onderzoeksthema's van 'Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib'. Samen vormen ze een unieke vingerafdruk.

Pharmacology, Toxicology and Pharmaceutical Science

Keyphrases